CN101766596A - Solid preparation with dextro-oxiracetam as active component - Google Patents
Solid preparation with dextro-oxiracetam as active component Download PDFInfo
- Publication number
- CN101766596A CN101766596A CN200910076436A CN200910076436A CN101766596A CN 101766596 A CN101766596 A CN 101766596A CN 200910076436 A CN200910076436 A CN 200910076436A CN 200910076436 A CN200910076436 A CN 200910076436A CN 101766596 A CN101766596 A CN 101766596A
- Authority
- CN
- China
- Prior art keywords
- oxiracetam
- solid preparation
- dextrorotation oxiracetam
- dextro
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a solid preparation with dextro-oxiracetam as an active component, relating to an oral preparation of the dextro-oxiracetam that is an annular derivant of hydroxyl aminobutyric acid (GABOB). The solid preparation contains the dextro-oxiracetam or salt or a purified hydrate thereof shown in the following structure; the chemical name is oxiracetam 4-hydroxy-pyrrolidine-2-ketone-1-acetamide; and the oral solid preparation is prepared by the dextro-oxiracetam and accessories that can be accepted in terms of pharmacy through the preparation technology. The dextro-oxiracetam which uses a single optical isomer can achieve better curative effect and milder toxic/side-effects than a racemate. The solid preparation of the dextro-oxiracetam is safe as well as effective, can be controlled and has stable quality.
Description
Technical field
The present invention relates to the preparation of a kind of synthetic hydroxy-amino-butyric acid (GABOB) cyclic derivatives dextrorotation oxiracetam.It is oral ordinary tablet, Film coated tablets, enteric coatel tablets, hard capsule and the granule that single dose dextrorotation oxiracetam and acceptable accessories are made by preparation technique.Use the dextrorotation oxiracetam of single optical isomer can obtain than raceme better therapeutic and lower toxic and side effects, dextrorotation oxiracetam solid preparation steady quality of the present invention, controlled, safe and effective belongs to medical technical field.
Background technology
Nootropics (nootropic oxiracetam) claims that again brain activin (cereboactive drug oxiracetam) is a kind of promotion study, the novel medicine for central nervous system of memory reinforcing.Glurgea is defined as nootropicdrug first.Nootropics requires selection in cerebral cortex, has to select to activate, protect and promote the feature that the injured nerve cell function recovers.Their above-mentioned effect that different with other neurologic agents a bit is is by reticular system or olfactory bulb, but directly acts on cortex.Neither influence behavior, also do not have calm excitation, so such medicine caused people's extensive concern and interest, the demand of such medicine has also been grown with each passing day.
Oxiracetam (oxiracetam) is a kind of synthetic hydroxy-amino-butyric acid (BABOB) cyclic derivatives; only act on the central nervous system; mainly be distributed in cerebral cortex, Hippocampus; the functional rehabilitation that activation, protection or promotion neurocyte are arranged; improve disturbance of intelligence patient's memory and learning functionality; and medicine itself does not have direct vasoactive, does not have the central excitation effect yet, is a kind of persistent facilitation to the influence of ability of learning and memory.The mechanism result of study shows, oxiracetam can promote the synthetic of phosphatidylcholine and PHOSPHATIDYL ETHANOLAMINE, promotes the brain metabolism, improves the stimulation of blood brain barrier to special nervus centralis road, improve the ratio of ATP/ADP in the brain, make the synthetic increase of protein and nucleic acid in the brain.
This medicine went on the market in Italy in 1987, and the dosage form of listing is a tablet, 800mg; Capsule, 800mg; Injection, 1g/5ml.At present domestic have only oxiracetam capsule and injection listing, and used main active is racemic modification.And we find after deliberation, and dextrorotation oxiracetam and racemic modification relatively have better therapeutic and toxic and side effects still less.
Summary of the invention
For improving pharmaceutically active, reduce toxicity, the invention provides a kind of single optical isomer dextrorotation oxiracetam solid preparation.
For achieving the above object, the present invention adopts following technical scheme:, a kind of, comprise the dextrorotation oxiracetam shown in the following structural formula or its salt or their purified hydrate; Chemical name is: oxiracetam-4-hydroxyl-pyrrolidin-2-one-1-acetamide; It is oral ordinary tablet, Film coated tablets, enteric coatel tablets, hard capsule, granule, oral cavity disintegration tablet, the effervescent tablet of making by preparation technique with single dose dextrorotation oxiracetam and acceptable accessories.
Molecular formula: C6H10N203
Molecular weight: 158.16
The content of dextrorotation oxiracetam is every dosage 50-1000mg; It comprises dextrorotation oxiracetam, binding agent, filler and disintegrating agent, and the weight composition of filler and disintegrating agent is respectively 10-60%, 2-30%.Also comprise fluidizer, lubricant and correctives, the weight composition of the two is respectively 1-5%, 0.2-3%, 0.01-2%.Wherein filler includes but not limited to lactose, sucrose, glucose, mannitol, sorbitol, calcium sulfate, calcium gluconate, calcium hydrogen phosphate, calcium phosphate, calcium carbonate, calcium bicarbonate, starch, carboxymethyl starch, pregelatinized Starch or microcrystalline Cellulose; Binding agent includes but not limited to starch, gelatin dextrin, maltodextrin, sucrose, arabic gum, polyvinylpyrrolidone, various viscosity methylcellulose, low viscosity carboxymethyl cellulose, various viscosity ethyl cellulose, various viscosity polyvinyl alcohol, polyethylene glycol 6000 or the following hyprolose of 50mpa oxiracetam; Disintegrating agent includes but not limited to pregelatinized Starch, microcrystalline Cellulose, alginic acid, pure wood fiber element, carboxymethyl starch sodium, guar gum, crospolyvinylpyrrolidone, methylcellulose or cross-linking sodium carboxymethyl cellulose; Lubricant includes but not limited to magnesium stearate, calcium stearate, Pulvis Talci, glyceryl monostearate, Macrogol 4000, polyethylene glycol 6000, Polyethylene Glycol 8000, sodium benzoate, adipic acid, fumaric acid, boric acid, sodium chloride, sodium laurylsulfate or magnesium laurylsulfate; Correctives includes but not limited to steviosin, sorbitol, maltose alcohol, glycyrrhizin, stem tea element, Sodium Cyclamate, flavoring banana essence, flavoring pineapple essence, Herba Menthae essence, Fructus Foeniculi, vanillin, Fructus Citri Limoniae essence, cherry essence or rose essence.
Pharmaceutical preparation of the present invention also comprises wetting agent, is purified water or ethanol etc.The used coating material of the present invention includes but not limited to cellulose and derivant thereof, crylic acid resin, ethene polymers etc.
The pharmacodynamics activity of dextrorotation oxiracetam solid preparation of the present invention is better than the oxiracetam racemic modification, and pharmacology's toxicity is then low than oxiracetam racemic modification, and steady quality, controlled, and is safe and effective.
The specific embodiment:
Following case study on implementation is used to explain the present invention, but is not limited thereto.
Embodiment 1
Make 1000 dextrorotation oxiracetam sheets with following materials of weight proportions.
Preparation technology:
1. dextrorotation oxiracetam raw material and adjuvant are crossed 80 mesh sieves respectively, and be standby.
2. get dextrorotation oxiracetam and pregelatinized Starch, the abundant mix homogeneously of microcrystalline Cellulose, with purified water system soft material, 18 mesh sieves are granulated, drying, granulate.
3. add carboxymethyl starch sodium and the abundant mix homogeneously of magnesium stearate, tabletting, promptly.
Embodiment 2
1. prepare 6% Opadry enteric coating agents alcoholic solution;
2. get the plain sheet of embodiment 1 gained, pour in the coating pan, start coating pan, and blowing hot-air, at 30-40 ℃ of preheating 10min, and blow plain sheet off adhere on the label medicated powder, evenly spray into coating solution, medicinal liquid is evenly coated on the label, promptly get dextrorotation oxiracetam enteric coatel tablets.
Embodiment 3:
Make 1000 dextrorotation oxiracetam sheets with the raw material of following weight ratio.
Preparation technology:
1. with dextrorotation oxiracetam raw material and adjuvant pulverize separately, cross 80 mesh sieves.
2. get dextrorotation oxiracetam and sorbitol, the abundant mix homogeneously of microcrystalline Cellulose, with water system soft material, 18 orders are granulated, 70 ℃ of oven dry, 18 order granulate.
3. add carboxymethyl starch sodium, the abundant mix homogeneously of magnesium stearate, tabletting, promptly.
Embodiment 4:
1. prepare the common gastric solubleness coating solution of Opadry
2. get the plain sheet of embodiment 3 gained, pour in the coating pan, start coating pan, and blowing hot-air, at 30-40 ℃ of preheating 10min, and blow plain sheet off adhere on the label medicated powder, evenly spray into coating solution, medicinal liquid is evenly coated on the label, promptly get dextrorotation oxiracetam general thin garment piece.
Embodiment 5:
Make 1000 dextrorotation oxiracetam capsules with following materials of weight proportions.
Preparation technology:
1. with dextrorotation oxiracetam raw material and adjuvant pulverize separately, cross 80 mesh sieves.
2. get the dextrorotation oxiracetam with 5% starch slurry system soft material, 24 orders are granulated, dry back granulate.
3. add carboxymethyl starch sodium, the abundant mix homogeneously of magnesium stearate, be packed in the capsulae vacuus promptly.
Embodiment 6:
Make 1000 dextrorotation oxiracetam capsules with following materials of weight proportions.
Preparation technology:
1,, crosses 80 mesh sieves with dextrorotation oxiracetam raw material pulverizing.
2, get the dextrorotation oxiracetam,, granulate, dry back granulate with 5%PVP solution system soft material.
3, add that cross-linked carboxymethyl fiber acid sodium produces, the abundant mix homogeneously of magnesium stearate, be packed in the capsulae vacuus promptly.
Embodiment 7
Make 1000 bags of dextrorotation oxiracetam granules with following materials of weight proportions,
Preparation technology:
Get dextrorotation oxiracetam and other each adjuvant, pulverize separately is crossed 80 mesh sieves, abundant mixing, and with purified water system soft material, 14 mesh sieves are granulated, drying, granulate, packing, promptly.
Embodiment 8
Make 1000 bags of dextrorotation oxiracetam granules with following materials of weight proportions,
Preparation technology:
Get dextrorotation oxiracetam and sucrose, pulverize, cross 80 mesh sieves, standby.Essence adds purified water 100ml dissolving, and with this solution system soft material, 14 mesh sieves are granulated, drying, and granulate, packing, promptly.
Embodiment 9
Make 1000 dextrorotation oxiracetam oral cavity disintegration tablets with following materials of weight proportions
Preparation technology:
1. with dextrorotation oxiracetam raw material and adjuvant pulverize separately, cross 80 mesh sieves.
2. getting dextrorotation oxiracetam and pregelatinized Starch, microcrystalline Cellulose, the abundant mix homogeneously of carboxymethyl starch sodium, is binding agent system soft material with water, and 24 mesh sieves are granulated, after the drying, and 24 mesh sieve granulate.
3. add cross-linking sodium carboxymethyl cellulose, sucralose, Fructus Citri Limoniae essence and the abundant mix homogeneously of magnesium stearate, tabletting, promptly.
Embodiment 10
Make 1000 dextrorotation oxiracetam oral cavity disintegration tablets with following materials of weight proportions
Preparation technology:
1. dextrorotation oxiracetam raw material and adjuvant are crossed 80 mesh sieves respectively.
2. with each supplementary material mix homogeneously, it is heavy to calculate sheet, tabletting.
Embodiment 11
Make 1000 dextrorotation oxiracetam effervescent tablets with following materials of weight proportions
Preparation technology:
1. with dextrorotation oxiracetam raw material and adjuvant pulverize separately, cross 80 mesh sieves.
2. get dextrorotation oxiracetam and tartaric acid, make soft material respectively with the 3%PVP aqueous solution, drying is controlled moisture content below 2%, and granulate is standby.
3. sodium bicarbonate is made soft material respectively with the 3%PVP aqueous solution, and drying is controlled moisture content below 2%, and granulate is standby.
4. with the abundant mix homogeneously of two parts granule, magnesium stearate, essence and sucralose, tabletting, promptly.
Embodiment 12
Make 1000 dextrorotation oxiracetam effervescent tablets with following materials of weight proportions
Preparation technology:
Each supplementary material is crossed 60 mesh sieves respectively, and dry in baking oven, moisture content is controlled at 2%, with the abundant mix homogeneously of each adjuvant, measures intermediate content, and it is heavy to calculate sheet, tabletting.
Claims (8)
- The present invention for a kind of be the solid preparation of active component with the dextrorotation oxiracetam, it comprises the dextrorotation oxiracetam shown in the following structural formula or its salt or their purified hydrate; Chemical name is: oxiracetam-4-hydroxyl-pyrrolidin-2-one-1-acetamide; It is the solid preparation of making by preparation technique with single dose dextrorotation oxiracetam and acceptable accessories, includes but not limited to following dosage form ordinary tablet, Film coated tablets, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, hard capsule, granule.
- 2. dextrorotation oxiracetam solid preparation as claimed in claim 1 is characterized in that the specification of the dextrorotation oxiracetam in described each prescription is per unit dosage 50-1500mg, is preferably 200-1200mg.
- 3. dextrorotation oxiracetam solid preparation as claimed in claim 1 is characterized in that, its acceptable accessories can be filler, binding agent, disintegrating agent, lubricant, correctives (necessity) and coating materials.
- 4. dextrorotation oxiracetam solid preparation as claimed in claim 3 is characterized in that filler includes but not limited to lactose, sucrose, glucose, mannitol, sorbitol, calcium sulfate, calcium gluconate, calcium hydrogen phosphate, calcium phosphate, calcium carbonate, calcium bicarbonate, starch, carboxymethyl starch, pregelatinized Starch, microcrystalline Cellulose, hydroxypropyl cellulose.
- 5. dextrorotation oxiracetam solid preparation as claimed in claim 3 is characterized in that binding agent includes but not limited to starch, gelatin, dextrin, maltodextrin, sucrose, arabic gum, polyvinylpyrrolidone, methylcellulose, carboxymethyl cellulose, ethyl cellulose, polyvinyl alcohol, polyethylene glycols or hyprolose.
- 6. dextrorotation oxiracetam solid preparation as claimed in claim 3 is characterized in that disintegrating agent includes but not limited to pregelatinized Starch, microcrystalline Cellulose, alginic acid, pure wood fiber element, carboxymethyl starch sodium, guar gum, crospolyvinylpyrrolidone, methylcellulose, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose or gas-producing disintegrant.
- 7. dextrorotation oxiracetam solid preparation as claimed in claim 3 is characterized in that lubricant includes but not limited to magnesium stearate, calcium stearate, zinc stearate, colloidal silica, sodium stearyl fumarate, Pulvis Talci, glyceryl monostearate, Macrogol 4000, polyethylene glycol 6000, Polyethylene Glycol 8000, sodium benzoate, adipic acid, fumaric acid, boric acid, leucine, sodium chloride, sodium laurylsulfate or magnesium laurylsulfate.
- 8. dextrorotation oxiracetam solid preparation as claimed in claim 3, it is characterized in that, the preparation technology of effervescent tablet is as follows, be principal agent is mixed with acid gas-producing disintegrant or other adjuvant and to granulate, dry, control moisture content is below 2%, again with alkaline dried particles (moisture content is below 2%) mixed pressuring plate; Or each supplementary material of will writing out a prescription dries, and mixture moisture content is controlled at below 2%, and powder directly carries out tabletting and gets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910076436A CN101766596A (en) | 2009-01-04 | 2009-01-04 | Solid preparation with dextro-oxiracetam as active component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910076436A CN101766596A (en) | 2009-01-04 | 2009-01-04 | Solid preparation with dextro-oxiracetam as active component |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101766596A true CN101766596A (en) | 2010-07-07 |
Family
ID=42499797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910076436A Pending CN101766596A (en) | 2009-01-04 | 2009-01-04 | Solid preparation with dextro-oxiracetam as active component |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101766596A (en) |
Cited By (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016184381A1 (en) * | 2015-05-18 | 2016-11-24 | 重庆润泽医药有限公司 | Use of dextrorotatory oxiracetam in pharmaceutical field |
| CN106890152A (en) * | 2015-12-17 | 2017-06-27 | 重庆润泽医药有限公司 | A kind of levo-oxiracetam effervescent tablet in good taste and preparation method thereof |
| CN106890156A (en) * | 2015-12-17 | 2017-06-27 | 重庆润泽医药有限公司 | It is a kind of to be disintegrated fast levo-oxiracetam effervescent tablet and preparation method thereof |
| CN106890153A (en) * | 2015-12-17 | 2017-06-27 | 重庆润泽医药有限公司 | A kind of good stability（S）Oxo-1-pyrrolidine ethanamide effervescent tablet of -4- hydroxyls -2 and preparation method thereof |
| CN106902092A (en) * | 2015-12-17 | 2017-06-30 | 重庆润泽医药有限公司 | A kind of disintegration is fast（S）Oxo-1-pyrrolidine ethanamide effervescent tablet of -4- hydroxyls -2 and preparation method thereof |
| CN106902091A (en) * | 2015-12-17 | 2017-06-30 | 重庆润泽医药有限公司 | A kind of delicious levo-oxiracetam effervescent tablet and preparation method thereof |
| CN108066295A (en) * | 2016-11-11 | 2018-05-25 | 重庆润泽医药有限公司 | Oxiracetam oral disnitegration tablet and preparation method thereof |
| CN108066293A (en) * | 2016-11-11 | 2018-05-25 | 重庆润泽医药有限公司 | A kind of method that pressed powder prepares Oxiracetam oral disnitegration tablet |
| CN109692167A (en) * | 2017-10-23 | 2019-04-30 | 重庆润泽医药有限公司 | The pharmaceutical composition and preparation method thereof for treating cognition dysfunction |
| CN109692166A (en) * | 2017-10-23 | 2019-04-30 | 重庆润泽医药有限公司 | The enteric slow release particle and preparation method thereof for treating epilepsy |
| CN109718222A (en) * | 2017-10-27 | 2019-05-07 | 重庆润泽医药有限公司 | Oxiracetam enteric coated preparations and preparation method thereof |
| CN110314139A (en) * | 2018-03-29 | 2019-10-11 | 重庆润泽医药有限公司 | The good dextrorotation oxiracetam lyophilized preparation and preparation method thereof of solubility |
| CN110314142A (en) * | 2018-03-29 | 2019-10-11 | 重庆润泽医药有限公司 | A kind of no crystal water dextrorotation oxiracetam freeze drying powder injection and preparation method thereof |
| CN110314141A (en) * | 2018-03-29 | 2019-10-11 | 重庆润泽医药有限公司 | A kind of dextrorotation oxiracetam freeze drying powder injection and preparation method thereof |
| CN110314144A (en) * | 2018-03-29 | 2019-10-11 | 重庆润泽医药有限公司 | The good dextrorotation Oxiracetam freeze drying powder injection and preparation method thereof of solubility |
| CN110327301A (en) * | 2018-03-29 | 2019-10-15 | 重庆润泽医药有限公司 | The good dextrorotation Oxiracetam freeze drying powder injection and preparation method thereof of stability |
| CN110384659A (en) * | 2018-04-17 | 2019-10-29 | 重庆润泽医药有限公司 | Injection dextrorotation oxiracetam powder-injection and preparation method thereof |
| CN110384664A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | Dextrorotation oxiracetam enteric coated particles and preparation method thereof |
| CN110384666A (en) * | 2018-04-23 | 2019-10-29 | 重庆润泽医药有限公司 | A kind of method of wet granule compression tablet preparation dextrorotation Oxiracetam tablet |
| CN110384671A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | Fluidized bed granulation prepares dextrorotation oxiracetam capsule and preparation method thereof |
| CN110384667A (en) * | 2018-04-23 | 2019-10-29 | 重庆润泽医药有限公司 | The method of dry granulation tabletting preparation dextrorotation Orazitan dispersion tablet |
| CN110384673A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | Dextrorotation oxiracetam capsule and preparation method thereof |
| CN110384662A (en) * | 2018-04-17 | 2019-10-29 | 重庆润泽医药有限公司 | A kind of injection dextrorotation oxiracetam and the composition of histidine and preparation method thereof |
| CN110384660A (en) * | 2018-04-17 | 2019-10-29 | 重庆润泽医药有限公司 | Injection dextrorotation Oxiracetam aseptic powdery and preparation method thereof |
| CN110384668A (en) * | 2018-04-23 | 2019-10-29 | 重庆润泽医药有限公司 | Fluidized bed granulation tabletting prepares dextrorotation oxiracetam enteric coatel tablets |
| CN110384674A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | Dextrorotation oxiracetam capsule and preparation method thereof |
| CN110384663A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | Dextrorotation oxiracetam particle of good fluidity and preparation method thereof |
| CN110384665A (en) * | 2018-04-23 | 2019-10-29 | 重庆润泽医药有限公司 | Crystal type dextrorotation oxiracetam tablet and preparation method thereof |
| CN110384672A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | The good dextrorotation oxiracetam capsule and preparation method thereof of stability |
| CN110384677A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | The good dextrorotation oxiracetam capsule and preparation method thereof of dissolution rate |
| CN110384676A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | The good dextrorotation oxiracetam capsule and preparation method thereof of stability |
| CN110384661A (en) * | 2018-04-17 | 2019-10-29 | 重庆润泽医药有限公司 | The good dextrorotation oxiracetam aseptic powdery and preparation method thereof of stability |
| CN110393707A (en) * | 2018-04-24 | 2019-11-01 | 重庆润泽医药有限公司 | Dextrorotation Oxiracetam enteric coatel tablets and preparation method thereof |
| CN110393704A (en) * | 2018-04-24 | 2019-11-01 | 重庆润泽医药有限公司 | A kind of dextrorotation Orazitan dispersion tablet and preparation method thereof |
| CN110393706A (en) * | 2018-04-24 | 2019-11-01 | 重庆润泽医药有限公司 | Dextrorotation oxiracetam enteric coatel tablets and preparation method thereof |
| CN110393802A (en) * | 2018-04-24 | 2019-11-01 | 重庆润泽医药有限公司 | Dextrorotation oxiracetam dispersible tablet and preparation method thereof |
-
2009
- 2009-01-04 CN CN200910076436A patent/CN101766596A/en active Pending
Cited By (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018515620A (en) * | 2015-05-18 | 2018-06-14 | 重慶潤澤医薬有限公司 | Application of dextrorotatory oxiracetam in the pharmaceutical field |
| CN106166150A (en) * | 2015-05-18 | 2016-11-30 | 重庆润泽医药有限公司 | The application in pharmaceutical field of the dextrorotation oxiracetam |
| EP3299016A4 (en) * | 2015-05-18 | 2019-02-27 | Chongqing Runze Pharmaceutical Co. Ltd. | Use of dextrorotatory oxiracetam in pharmaceutical field |
| WO2016184381A1 (en) * | 2015-05-18 | 2016-11-24 | 重庆润泽医药有限公司 | Use of dextrorotatory oxiracetam in pharmaceutical field |
| CN106890156A (en) * | 2015-12-17 | 2017-06-27 | 重庆润泽医药有限公司 | It is a kind of to be disintegrated fast levo-oxiracetam effervescent tablet and preparation method thereof |
| CN106902092A (en) * | 2015-12-17 | 2017-06-30 | 重庆润泽医药有限公司 | A kind of disintegration is fast（S）Oxo-1-pyrrolidine ethanamide effervescent tablet of -4- hydroxyls -2 and preparation method thereof |
| CN106902091A (en) * | 2015-12-17 | 2017-06-30 | 重庆润泽医药有限公司 | A kind of delicious levo-oxiracetam effervescent tablet and preparation method thereof |
| CN106890153A (en) * | 2015-12-17 | 2017-06-27 | 重庆润泽医药有限公司 | A kind of good stability（S）Oxo-1-pyrrolidine ethanamide effervescent tablet of -4- hydroxyls -2 and preparation method thereof |
| CN106890152A (en) * | 2015-12-17 | 2017-06-27 | 重庆润泽医药有限公司 | A kind of levo-oxiracetam effervescent tablet in good taste and preparation method thereof |
| CN108066295A (en) * | 2016-11-11 | 2018-05-25 | 重庆润泽医药有限公司 | Oxiracetam oral disnitegration tablet and preparation method thereof |
| CN108066293A (en) * | 2016-11-11 | 2018-05-25 | 重庆润泽医药有限公司 | A kind of method that pressed powder prepares Oxiracetam oral disnitegration tablet |
| CN109692167A (en) * | 2017-10-23 | 2019-04-30 | 重庆润泽医药有限公司 | The pharmaceutical composition and preparation method thereof for treating cognition dysfunction |
| CN109692166A (en) * | 2017-10-23 | 2019-04-30 | 重庆润泽医药有限公司 | The enteric slow release particle and preparation method thereof for treating epilepsy |
| CN109718222A (en) * | 2017-10-27 | 2019-05-07 | 重庆润泽医药有限公司 | Oxiracetam enteric coated preparations and preparation method thereof |
| CN110327301A (en) * | 2018-03-29 | 2019-10-15 | 重庆润泽医药有限公司 | The good dextrorotation Oxiracetam freeze drying powder injection and preparation method thereof of stability |
| CN110314142A (en) * | 2018-03-29 | 2019-10-11 | 重庆润泽医药有限公司 | A kind of no crystal water dextrorotation oxiracetam freeze drying powder injection and preparation method thereof |
| CN110314141A (en) * | 2018-03-29 | 2019-10-11 | 重庆润泽医药有限公司 | A kind of dextrorotation oxiracetam freeze drying powder injection and preparation method thereof |
| CN110314144A (en) * | 2018-03-29 | 2019-10-11 | 重庆润泽医药有限公司 | The good dextrorotation Oxiracetam freeze drying powder injection and preparation method thereof of solubility |
| CN110314139A (en) * | 2018-03-29 | 2019-10-11 | 重庆润泽医药有限公司 | The good dextrorotation oxiracetam lyophilized preparation and preparation method thereof of solubility |
| CN110384661A (en) * | 2018-04-17 | 2019-10-29 | 重庆润泽医药有限公司 | The good dextrorotation oxiracetam aseptic powdery and preparation method thereof of stability |
| CN110384659A (en) * | 2018-04-17 | 2019-10-29 | 重庆润泽医药有限公司 | Injection dextrorotation oxiracetam powder-injection and preparation method thereof |
| CN110384662A (en) * | 2018-04-17 | 2019-10-29 | 重庆润泽医药有限公司 | A kind of injection dextrorotation oxiracetam and the composition of histidine and preparation method thereof |
| CN110384660A (en) * | 2018-04-17 | 2019-10-29 | 重庆润泽医药有限公司 | Injection dextrorotation Oxiracetam aseptic powdery and preparation method thereof |
| CN110384664A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | Dextrorotation oxiracetam enteric coated particles and preparation method thereof |
| CN110384671A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | Fluidized bed granulation prepares dextrorotation oxiracetam capsule and preparation method thereof |
| CN110384672A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | The good dextrorotation oxiracetam capsule and preparation method thereof of stability |
| CN110384673A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | Dextrorotation oxiracetam capsule and preparation method thereof |
| CN110384676A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | The good dextrorotation oxiracetam capsule and preparation method thereof of stability |
| CN110384674A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | Dextrorotation oxiracetam capsule and preparation method thereof |
| CN110384663A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | Dextrorotation oxiracetam particle of good fluidity and preparation method thereof |
| CN110384677A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | The good dextrorotation oxiracetam capsule and preparation method thereof of dissolution rate |
| CN110384666A (en) * | 2018-04-23 | 2019-10-29 | 重庆润泽医药有限公司 | A kind of method of wet granule compression tablet preparation dextrorotation Oxiracetam tablet |
| CN110384665A (en) * | 2018-04-23 | 2019-10-29 | 重庆润泽医药有限公司 | Crystal type dextrorotation oxiracetam tablet and preparation method thereof |
| CN110384668A (en) * | 2018-04-23 | 2019-10-29 | 重庆润泽医药有限公司 | Fluidized bed granulation tabletting prepares dextrorotation oxiracetam enteric coatel tablets |
| CN110384667A (en) * | 2018-04-23 | 2019-10-29 | 重庆润泽医药有限公司 | The method of dry granulation tabletting preparation dextrorotation Orazitan dispersion tablet |
| CN110393707A (en) * | 2018-04-24 | 2019-11-01 | 重庆润泽医药有限公司 | Dextrorotation Oxiracetam enteric coatel tablets and preparation method thereof |
| CN110393704A (en) * | 2018-04-24 | 2019-11-01 | 重庆润泽医药有限公司 | A kind of dextrorotation Orazitan dispersion tablet and preparation method thereof |
| CN110393706A (en) * | 2018-04-24 | 2019-11-01 | 重庆润泽医药有限公司 | Dextrorotation oxiracetam enteric coatel tablets and preparation method thereof |
| CN110393802A (en) * | 2018-04-24 | 2019-11-01 | 重庆润泽医药有限公司 | Dextrorotation oxiracetam dispersible tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101766596A (en) | Solid preparation with dextro-oxiracetam as active component | |
| CN101766595A (en) | Solid preparation with levo-oxiracetam as active component | |
| CN103989650A (en) | Orally disintegrating pharmaceutical composition and preparation method thereof | |
| CN101278932A (en) | Sustained release medicinal compositions containing Zaltoprofen, preparation method and application thereof | |
| CN101401797A (en) | Effervescent tablet containing imatinib mesylate and preparation method thereof | |
| CN101862333B (en) | Stable sodium levofolinate oral preparation and preparation method thereof | |
| CN101152155A (en) | Hydrochloric acid Ivabradine solid pharmaceutical composition and method for preparing the same | |
| CN102488681A (en) | Ibuprofen diphenhydramine orally disintegrating tablet and preparation method thereof | |
| CN101642461B (en) | Drug composition of iguratimod and glucosamine, preparation method and drug application thereof | |
| CN101991559B (en) | Stable agomelatine capsule pharmaceutical composition | |
| CN101836996A (en) | Oral solid preparation using loperamide hydrochloride and simethicone as main ingredients | |
| CN101636153A (en) | Time-specific delayed/pulsatile release dosage forms | |
| CN106074429A (en) | A kind of Vonoprazan fumarate effervescent tablet and preparation method thereof | |
| CN102727456B (en) | Drug port cavity disintegrating tablet and preparation method thereof | |
| CN102755310B (en) | A kind of composition medicine preparation containing levodopa | |
| CN101756947A (en) | Compound solid preparation for treating asthma | |
| CN102125540A (en) | Pharmaceutically acceptable composition containing ambroxol in non-salt form | |
| CN101700245B (en) | Compound drug for curing colds and preparation technology thereof | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CN102846555A (en) | Solid preparation comprising pirfenidone as active component and application thereof | |
| CN101991577A (en) | Novel mental medicinal composition | |
| CN102836162A (en) | Oral solid preparation taking tofisopam as active ingredient and application of oral solid preparation | |
| CN101829137A (en) | Solid preparation with citicoline sodium and inosine as active ingredients and applications thereof | |
| CN103976967A (en) | Ginkgolide sublingual tablet and preparation method thereof | |
| CN1861056B (en) | Slow-releasing preparation containing gastrodin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100707 |